We are delighted to welcome this year’s presenting companies taking stage in May at MedtechInvest 2025.
The company profiles are listed in alphabetical order from A to Z. Click on each logo to jump to their information and explore their innovative solutions.
Additive Surgical is the first company in Australia to manufacture off-the-shelf 3D printed titanium spinal implants, using state-of-the-art European IP. Established in 2020, the team is committed to producing high-quality medical technologies that improve lives globally.
Convergence Medical is a startup building the world’s first arthroscopic (minimally invasive keyhole joint surgery) surgical robot named the V01. Convergence Medical has raised over $4M AUD to date and recently signed our series A term sheet for an additional USD$5M investment to soft launch the V01 platform. As there are over 50 million arthroscopic procedures performed every year and over 40% are impacted by problems related to the use of outdated and manual equipment, we believe that the V01 is on track to change the landscape for arthroscopy globally.
Cyban is developing a novel non-invasive brain blood flow monitor to improve early detection of stroke and other brain injuries in sedated or unconscious patients. Its patented technology combines proprietary sensors and signal processing to deliver continuous, accurate data from trauma site to hospital discharge advancing diagnosis, treatment and outcomes in critical care.
EMVision is an Australian listed medtech company developing world-first portable brain scanners to address major unmet clinical needs. Founded in 2017 to advance research from the University of Queensland, EMVision is led by a team with deep expertise in medical device development and commercialisation.
Examin Holdings Pty Ltd is an Australian medtech company developing a handheld breathalyzer that detects COVID-19 in under two minutes using patented quantum tunneling technology. The device delivers PCR-comparable accuracy in a fast, non-invasive format ideal for airports and workplaces. With disposable mouthpieces and scalable design, Examin is expanding its platform to detect viruses like Influenza A/B, RSV and Tuberculosis. Regulatory approval is expected in 2025.
Gelomics revolutionises drug development by enabling pharmaceutical companies to grow functional human tissues in a petri dish—delivering superior preclinical predictivity, accelerating time to market, and replacing animal testing with a scalable, ethical alternative. Named KPMG’s Australian Tech Innovator 2024, the company has bootstrapped through MVP development, raised over $4 million in venture and non-dilutive funding, and validated its platform with more than 300 paying customers across 23 countries, achieving an 80% demo-to-sales conversion rate. Gelomics is now raising its 2025 Seed round to launch next-generation products and expand into the US market.
Haemograph is developing a compact, portable diagnostic platform that analyses blood flow and clotting in real time offering insights beyond standard lab tests. Initially targeting haematology and critical care, the system aims to support clinicians with rapid, actionable data at the bedside.
High Fidelity Orthopaedics is transforming trauma care with its world-first Medical Device Production System (MDPS), enabling rapid, patient-specific orthopaedic implants at the point of care. By combining AI, imaging and 3D printing, the platform streamlines surgery, reduces hospital burden, and bypasses traditional supply chain delays. With strong clinical partnerships and a focus on global access, the company is redefining personalised, just-in-time orthopaedics.
Integrant is an Australian biotechnology company pioneering innovations in orthopaedic regenerative medicine. Building on its portfolio in bone healing and surgical precision, the company is advancing a novel and noninvasive therapy for osteoarthritis that regenerates meniscus cartilage through injection, offering an alternative to knee replacement surgery.
Kardiomics is an Australian diagnostics company developing a qPCR test for the early detection of cardiovascular inflammation. The test targets SMuRF less patients, who present with first time heart attacks without standard risk factors, and supports monitoring of therapy effectiveness in patients with existing cardiovascular disease. Addressing a large global market, the test aims to fill a critical gap in cardiovascular risk detection and disease management.
Navi Medical Technologies is an Australian medtech company enhancing central line placement in neonatal and paediatric intensive care. Its Neonav® ECG Tip Location System provides real-time guidance for central venous access devices (CVADs) using intravascular ECG. Following FDA clearance in early 2025, Navi is preparing for commercial launch in the US, EU and Australia, addressing a global market worth over AUD 1 billion.
VenstraMedical is an Australian medtech company developing the smallest and most powerful percutaneous cardiac assist device for patients with cardiogenic shock and those undergoing high risk coronary interventions. The low-profile pump delivers up to 7 litres per minute of support and collapses into a 9Fr catheter for insertion across the aortic valve. Backed by 7 issued patents, the company is preparing for Series B to fund clinical trials, with strong strategic and institutional interest.
